Linkage to Hepatitis C Care Following Release from Jail: A Prospective, Single Arm Clinical Trial

CURRENT STATUS: ACCEPTED

Matthew Jiro Akiyama
Montefiore Medical Center/Albert Einstein College of Medicine

makiyama@montefiore.org Corresponding Author
ORCiD: https://orcid.org/0000-0003-4290-3083

Devin Columbus
New York University School of Medicine

Ross MacDonald
New York City Health + Hospitals

Alison O Jordan
New York City Health + Hospitals

Jessie Schwartz
New York City Department of Health and Mental Hygiene

Alain H Litwin
Greenville Health System, University of South Carolina School of Medicine

Benjamin Eckhardt
New York University School of Medicine

Ellie Carmody
New York University School of Medicine

DOI: 10.21203/rs.2.10021/v1

SUBJECT AREAS
Infectious Diseases

KEYWORDS
HCV, jail, prison, linkage to care, PWID
Abstract
Background: Hepatitis C virus (HCV) is a major public health problem in correctional settings. HCV treatment is often not possible in U.S. jails due to short lengths of stay. Linkage to care is crucial in these settings, but competing priorities complicate community healthcare engagement and retention after incarceration.

Methods: We conducted a single arm clinical trial to assess the rate and factors associated with linkage to HCV care after incarceration associated with a combined transitional care coordination (TCC) and patient navigation intervention.

Results: During the intervention, n=84 participants returned to the community after their index incarceration. Most participants were male and Hispanic, with a history of mental illness and a mean age of 45 years (SD=12). Of those who returned to the community, 26 (31%) linked to HCV care within a mean of 29 days (SD=25); 17 (20%) initiated HCV treatment, 15 (18%) completed treatment, and 7 (8%) had documentation of sustained virologic response. Expressing a preference to be linked to the participant’s existing health system, being on methadone prior to incarceration, and feeling that family or a loved one were concerned about the participant’s wellbeing were associated with linkage to HCV care. Reporting drinking alcohol to intoxication prior to incarceration was negatively associated with linkage to HCV care.

Conclusion: We demonstrate that an integrated strategy with combined TCC and patient navigation may be effective in achieving timely linkage to HCV care. Additional multicomponent interventions aimed at treatment of substance use disorders and increasing social support could lead to further improvement.

Introduction
As many as half a million people in correctional settings in the United States may be hepatitis C virus (HCV) antibody-positive.1 Due in part to the criminalization of individuals with substance use disorders known to increase HCV risk, HCV prevalence in correctional settings is in the order of 10-20 times that of the surrounding community.2 It is estimated that one in three people living with HCV (PLWHCV) pass through the criminal justice system each year.3 Failure to effectively intervene for PLWHCV in
HCV care within the criminal justice system may place PLWHCV at ongoing risk for progression of HCV-related liver disease (cirrhosis, end-stage liver disease, and hepatocellular carcinoma) and may facilitate ongoing transmission of HCV in the neighborhoods of greatest socio-economic disparities to which PLWHCV return after incarceration.4-6

The criminal justice system, being a high prevalence setting, is an important locus for HCV treatment with the goal of HCV elimination.7 For optimal operationalization of a response to HCV in this setting it is important to differentiate jails from prisons. People incarcerated in local jails are largely detained pre-trial and/or have short sentences of generally up to one year or less. People incarcerated in prisons are convicted of a crime and typically sentenced to incarceration for more than one year. While longer sentences more readily permit HCV treatment in prisons, treatment is complicated in jails where the median length of stay is 15 days.8 HCV regimens have been reduced to twelve weeks or less for the majority of individuals with direct acting antiviral (DAA) therapy making treatment feasible for some jail detainees.9 However, there are twelve million admissions to US jails per year, which is nineteen times the number in state and federal prisons.10 With the high volume of likely untreated detainees cycling through, U.S. jails are a critical site for linkage to HCV care after incarceration.

Linkage to community care from correctional settings is complicated by competing priorities following release. During incarceration, individuals experience social, structural, and medical disruptions that complicate the reentry period. To date, the majority of work on linkage to care from correctional settings has focused on people living with HIV (PLWHIV). Lack of access to health insurance, lack of social support, exacerbation of mental health conditions, and unstable housing have all been documented as complicating linkage to care among PLWHIV.11-14

A variety of strategies have been evaluated for their impact on linkage to care among PLWHIV leaving jail and prison. Case management, which aims to coordinate medical, mental health, social, and other services has been the most extensively studied. Evidence suggests that case management plays a key role in facilitating linkage to HIV care. In one randomized controlled trial (RCT), case management
was shown to be more effective than referral alone.\textsuperscript{15} Case management has also been associated with improved adherence to antiretroviral therapy (ART), HIV viral load suppression, retention in care, fewer emergency department visits, and less housing instability and food insecurity among PLWHIV.\textsuperscript{16,17} Transitional care coordination (TCC) is a form of case management that includes an intake assessment, discharge and transitional care plans, and appointment scheduling. TCC is now a nationally recognized evidence-informed intervention that plays a key role in facilitating linkage to HIV care after incarceration.\textsuperscript{18} Patient navigation is another strategy that may provide additional benefit. While patient navigation does not have a standard definition, programs incorporating this strategy tend to focus on advocacy, health education, and social support.\textsuperscript{19} In a recently published RCT study, patient navigation coupled with case management resulted in greater linkage to and retention in HIV care following release from jail than standard case management alone.\textsuperscript{20} Strategies for linkage to HIV care are applicable to other clinical and therapeutic areas including HCV. To date, models of care and their impact on linkage to HCV care following release from correctional settings are poorly understood. There are also few data on predictors of linkage to HCV care following release. We conducted a prospective, single arm clinical trial of a combined TCC and patient navigation intervention among HCV mono-infected individuals leaving the New York City jail system. The goal of this study was to assess the impact of this combined TCC and patient navigation model on the rate of linkage to and retention in HCV care. We also aimed to identify factors associated with linkage to HCV care and evaluate feasibility of operationalizing this care coordination strategy among justice-involved PLWHCV.

Methods

Study setting and participants

The NYC jail system is the second largest in the U.S. with nearly fifty thousand admissions per year and an average daily census of over eight thousand (as of 2018).\textsuperscript{21} Health care service delivery in jails is the responsibility of Correctional Health Services, a division of NYC Health + Hospitals, the nation’s largest public health care system.\textsuperscript{21} We identified potential participants using clinical data
reports identifying individuals with detectable HCV viral loads. Recruitment was conducted in three NYC jails and one hospital correctional health ward (Bellevue Hospital). We included consenting patients who were ≥18 years old at time of recruitment, were diagnosed with chronic HCV, and had a projected length of stay sufficient to anticipate community reentry within the study follow-up period. Exclusion criteria included HIV (due to existing TCC services on a population basis) and inability to obtain informed, signed consent. We conducted study enrollment and baseline interviews in private cubicles of jail health clinics.

**Participant tracking**

We tracked dates of incarceration and community return by querying public inmate lookup databases\(^{22,23}\) and communicating with jail health staff throughout the course of the study. Index incarceration was defined as the incarceration during which study enrollment and baseline interview took place. Reincarceration was defined as any incarceration of duration of greater than 24 hours occurring after release from an index incarceration.

We collected detailed contact information for participants and participants’ next of kin (NOK) to facilitate patient navigation upon reentry into the community. We also collected information on places and programs the participant may have frequented in the community (e.g., drug treatment centers; homeless shelters).

**HCV transitional care coordination & patient navigation**

We partnered with New York City Correctional Health Services teams that employ the well-established TCC intervention to facilitate linkages to care for PLWHIV after incarceration in the NYC jail system.\(^{18}\) The TCC intervention includes: intake and assessment services, discharge planning, health insurance assistance, court liaison to facilitate medical alternatives to incarceration, facilitating continuity of medication and patient navigation and coordination with service providers to facilitate linkages to care after incarceration.\(^{12}\) We developed a care coordination intervention employing a similar model for HCV mono-infected detainees with HCV education and community patient navigation performed by a master’s level study coordinator. Patient navigation included reminder calls, appointment
rescheduling if needed, appointment accompaniment if requested, and free public transit passes for each successfully completed HCV appointment. Patient navigation did not include home visits or direct outreach due to resource limitations. We gave all participants contact information for key study team members and encouraged communication before and after release.

Study personnel offered participants assistance with scheduling HCV linkage appointments at their existing health system, if applicable, or one of two study-affiliated community clinical partners if they preferred. Appointment dates were targeted within two to four weeks of projected release. Whether or not a community appointment was scheduled during the jail stay, we attempted to engage all participants within one week after incarceration using information from the enrollment interview. This included attempting to contact participants and/or NOK via telephone, text, and/or email. Participants were followed for up to 180 days after the index incarceration during which time attempts were made at linkage to HCV care.

For participants contacted after incarceration, we made up to five attempts to schedule community HCV appointments within 180 days after the index incarceration before categorizing a participant as not linked. If the participant was reincarcerated prior to or after being linked to HCV care, we attempted to coordinate follow-up appointments after reincarceration. For participants who linked to care, study personnel assisted with scheduling HCV clinical and laboratory follow-up visits.

Data sources and covariates

Following enrollment, we conducted participant interviews using a modified version of the Addiction Severity Index (ASI) to identify potential factors associated with linkage to HCV care. The ASI includes information on medical history, employment/financial support, drug/alcohol use (e.g., Have you used heroin in your lifetime; how many days did you use heroin in the 30 days prior to incarceration?), legal case status, family/social relationships, and psychiatric status. Individual participants’ answers were recorded by a study coordinator and entered into REDCap – a secure, web-based application designed to support data capture for research studies. Feasibility data were gathered from study staff logs detailing the number of attempted and successful contacts with participants/NOKs. Data on linkage to and retention in HCV care were obtained from participant medical records.
Primary and secondary outcomes

Our primary outcome was linkage to HCV care, which was defined as a documented visit with an HCV treating provider within 180 days after release. Once linked to care, clinicians assessed participants for HCV treatment eligibility according to standard of care. Secondary outcomes for treatment-eligible participants included treatment initiation, treatment completion, and documented sustained virologic response (SVR), or HCV cure.

Statistical analysis

We conducted a bivariate analysis to examine associations with linkage to HCV care using Chi-square and Fisher’s exact tests for categorical variables. Significance was assessed at an alpha level of 0.05. Statistical analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC). We also used EventFlow (University of Maryland, Human-Computer Interaction Lab; http://hcil.umd.edu/eventflow) to identify relevant temporal event sequences associated with the HCV corrections-community care cascade with an emphasis on linkage to HCV care and reincarceration.

Statement of ethical standards

The study team obtained written informed consent from all participants enrolled in the study, and approval to conduct the study was obtained from New York University School of Medicine and New York City Department of Health and Mental Hygiene Institutional Review Boards (IRB). The New York University School of Medicine IRB approval process encompassed detailed review by the IRB prisoners’ advocate.

Results

Participants

From May 2015 to April 2017 we identified and interviewed 185 people incarcerated in NYC jails for study participation; a total of 105 were enrolled and 5 were subsequently disenrolled as PLWHIV from the study group, leaving a cohort of 100 who were followed during and after their index incarceration. Of the 100 participants, 8 were transferred to state prison or another jurisdiction, 4 received HCV treatment in jail, 1 spontaneously cleared their HCV infection, 1 died prior to release, and 2 remained incarcerated at the completion of the study; leaving 84 who returned to the community after the
index incarceration (Figure 1).

Most participants were male (57%) and Hispanic (55%) with a mean age of 45 years (SD=12). The majority (63%) had a reported history of mental illness. Over one quarter (26%) reported being homeless prior to incarceration. Most (81%) participants reported having health insurance in the community, but fewer than one quarter (24%) had an existing primary care provider and fewer than 10% had an existing HCV provider. Over two thirds (70%) reported a lifetime history of injection drug use and nearly two thirds (61%) reported injection drug use in the 30 days prior to incarceration. Most (89%) reported using heroin in their lifetime and over half reporting heroin use in the 30 days prior to incarceration. Nearly two thirds (60%) reported taking methadone prior to incarceration and nearly one third (29%) reported taking buprenorphine-naloxone (Table 1).

**HCV transitional care coordination & patient navigation**

The mean duration of time between enrollment and community return after the index incarceration was 70.5 days (SD=101.6). Less than one half (43%) provided personal contact information, but almost all provided contact information for a NOK (92%). On average, participants were engaged 1.2 (SD=0.5) times by study staff during incarceration. In the 180 days after incarceration, an average of 3.8 (SD=4.4) contact attempts were made resulting in 42 (50%) participants being successfully contacted, and an average of 2.7 (SD=2.1) attempts to contact NOKs resulted in 53 (63%) successful contacts of participants’ NOK.

**Linkage to & retention in HCV care**

Of the participants who returned to the community after the index incarceration, 26 (31%) linked to HCV care within a mean of 29.0 days (SD=25.0). On average, 1.1 (SD=1.1) linkage appointments were made per participant. In terms of secondary outcomes, 17 (20%) participants initiated HCV treatment, 15 (18%) completed treatment, and 7 (8%) had a documented SVR (Figure 2). Among those who completed treatment, 9 participants had a blood draw 12 weeks following treatment completion; therefore, the known SVR rate was (7/9) 78%.

**Reincarceration**

Overall, 28 (33%) participants were reincarcerated within a mean of 96.3 days (SD=74.9) after their
index incarceration. Reincarceration was an equally common initial event compared with linkage to HCV care with 23 (27%) participants being reincarcerated following community return. Five participants who were linked to HCV care were subsequently reincarcerated. Conversely, three participants who were reincarcerated subsequently linked to HCV care after incarceration. Nearly half (45%) of study participants were either not known to be linked to HCV care or reincarcerated in the 180 days after their index incarceration (Figure 3).

**Associations with linkage to HCV care**

Expressing a preference to be linked to the participant’s existing health system, being on methadone prior to incarceration, and feeling that family or a loved one were concerned about the participant’s wellbeing were associated with linkage to HCV care. Reporting drinking alcohol to intoxication prior to incarceration was negatively associated with linkage to HCV care. Reincarceration and homelessness were not found to be significantly associated with linkage to HCV care (Table 1).

**Discussion**

To our knowledge, this is the first prospective trial to characterize the HCV care cascade in the transition from a correctional setting to the community. It is also the first cohort study to describe factors associated with linkage to HCV care following release from incarceration. These data provide preliminary evidence that a combined TCC and patient navigation strategy may be effective in achieving timely linkage to HCV care for a subset of PLWHCV following release from jail.

Linkage rates in our study are similar to those reported in other corrections-based public health programs and pilot studies from other jurisdictions. In a Rhode Island-based rapid HCV testing pilot study in which participants received a questionnaire, informational video, and a referral, 4/15 (27%) participants with confirmed viremia linked to HCV care. In a Massachusetts program in which participants with HCV received referrals to HCV care, 14/82 (17%) and 31/82 (38%) had laboratory evidence of linkage to HCV care within 6 and 12 months, respectively. In an HCV testing and linkage to care program in South and North Carolina, participants received HCV post-test counseling, a referral, appointment scheduling, and patient navigation (in North Carolina only). In South and North Carolina, respectively, 2/7 (28%) and 10/18 (56%) participants who were referred attended their first
HCV appointment.\textsuperscript{27}

All of these studies suggest there are substantial challenges associated with linkage to HCV care. Moreover, data from South Carolina, Massachusetts, and Rhode Island demonstrate these barriers are not overcome with education, referral, and appointment scheduling alone. While data from North Carolina suggest better linkage rates may be achievable with patient navigation, the small sample size limits the generalizability of the results and, still, only roughly half of participants linked to HCV care. Our intervention was modeled on the evidence-informed TCC intervention used in NYC jails to facilitate linkage to HIV care after incarceration. For PLWHIV, linkage rates associated with this program approach 75\%.\textsuperscript{18} Yet, the linkage rate was substantially lower among monoinfected PLWHCV in our study.

Several factors may account for the higher linkage rate among PLWHIV than PLWHCV. First, in our study we used telephone-based patient navigation with appointment accompaniment if requested as the community portion of the intervention. The TCC intervention for PLWHIV after incarceration in the NYC jails includes an extensive network of community resources, linkage agreements with community providers, dedicated community case managers funded through Ryan White Part A, and housing assistance.\textsuperscript{28} We were not able to provide such extensive services due to resource limitations and believe such services could have improved linkage rates.\textsuperscript{18}

We hypothesize there are several other key differences leading to higher linkage rates among PLWHIV than PLWHCV. First, due to the earlier response of health care systems to the HIV epidemic at the federal, state, and local levels and relatively longstanding availability of effective ART, many PLWHIV are more informed about their HIV diagnoses and the effectiveness of ART. As an example, Loeliger et al. demonstrated that an HIV diagnosis of greater than one year predicted retention in HIV care among justice-involved PLWHIV.\textsuperscript{17} PLWHCV may be relatively unaware of the short- and long-term consequence of HCV infection and the effectiveness of DAA therapy. With increased collective HCV-and DAA-related knowledge, linkage rates may marginally improve over time.

Additionally, relationships with medical providers prior to incarceration have been shown to result in
higher linkage rates among PLWHIV. Our study mirrors this finding given a preference to be linked to one’s existing health system was associated with linkage to HCV care. Among PLWHIV who reported no prior history of HIV medical services, Molitor et al. identified a linkage rate of 29%. Very few of our study participants reported an existing relationship with an HCV provider prior to incarceration, and our linkage rate was similar. Taken together, these findings suggest increased familiarity with the healthcare system may facilitate linkage to care.

Active substance use disorders also likely contribute to lower linkage rates among PLWHCV. Injection drug use is the number one risk factor for HCV in the U.S., and nearly two-thirds of our study participants reported injection drug use thirty days prior to incarceration. Substance use disorders are known to complicate linkage among PLWHIV. In our study, injection drug use was not associated with linkage to HCV care; however, taking methadone prior to incarceration was. Opioid agonist therapy is an evidence-based strategy leading to more stability from active drug use and higher linkage to care among PLWHIV. While we do not have follow-up data on continuation of methadone, we presume many of these participants continued on methadone as those who were on methadone prior to incarceration at the time of this study were generally maintained in the NYC jails unless they were expected to be transferred to prison based on available legal criteria. Given that the period following release is associated with a high risk for active drug use and theoretical risk for HCV transmission, rapid linkages to HCV and substance use disorder treatment are a high priority. The importance of linkage interventions among people who inject drugs is further underscored by risk of overdose following release from correctional settings.

Reporting a history of drinking alcohol to intoxication prior to incarceration was negatively associated with linkage to HCV care. Data are limited on the impact of alcohol use on linkage to care following incarceration. However, alcohol has been shown to be negatively associated with DAA adherence among people who inject drugs. Drinking alcohol to intoxication in the 30 days prior to incarceration was not associated with linkage to care; however, it did show a similar trend. Therefore, screening and treatment of alcohol use disorders should also be considered an integral component of HCV
linkage to care programs.

Feeling family or a loved one were concerned about the participants’ wellbeing was also associated with linkage to HCV care in our study. The role of social support in promoting linkage to care among PLWHCV following release from correctional settings is not known; however, there is evidence among PLWHIV that a lack of social support is a barrier. The use of patient or peer navigators with racial/ethnic concordance or shared life experience have been proposed as an important strategy.\textsuperscript{31,39,40} This may be even more important for those who lack support from family or a loved one. In our study, a navigator with a master’s level of education performed patient navigation that was mostly telephonic. It is possible peer navigation with active outreach might have resulted in a higher linkage rate.

We did not identify a statistically significant relationship between reincarceration and linkage to HCV care. Reincarceration has been demonstrated to be a complicating factor in linkage to and retention in HIV care. However, since detainees have access to stable medical services, it can also be leveraged to improve HIV-related outcomes.\textsuperscript{17,41,42} In our study, reincarceration was more common in the 180 days following release than linkage to HCV care and was an equally common initial event compared to HCV care. If individuals are reincarcerated, communication can be interrupted and HCV linkage appointments may be missed. Conversely, reincarceration may be an opportunity to reengage individuals with HCV who have not yet linked to care, as was the case for three participants in this study.

This study has several limitations. First, as a single arm trial, we are unable to determine if the observed linkage rate was directly attributable to the intervention. However, we believe our study provides important baseline data on the rate of linkage to HCV care associated with a combined case management and patient navigation strategy. Second, the study took place in one large urban area, and community partners were able to schedule HCV appointments within 2-4 weeks of release, which may limit generalizability. Third, our sample may not have been representative of PLWHCV in the jail population as a whole since the mean duration of time between enrollment and release was 70.5
days, and detainees with the shortest lengths of stay were not able to be recruited. Fourth, demographics and covariates like mental illness were obtained through self-report, which may under- or overestimate true rates. Lastly, participants who were lost to follow-up could have linked to non study-affiliated clinics so our linkage rate may be underestimated.

Despite these limitations, our study provides important real-world data on the rate and factors associated with linkage to HCV care following release from jail. Due to the modest linkage rates observed, future interventions should consider strengthening transitional care planning and community patient navigation among justice-involved PLWHCV. We believe that multicomponent intervention incorporating education, increased resources for TCC and community-based patient navigation, treatment of substance use disorders – specifically concomitant linkage to opioid agonist therapy, and increasing social support are needed.

Declarations

Ethics approval and consent to participate: The study team obtained written informed consent from all participants enrolled in the study, and approval to conduct the study was obtained from New York University School of Medicine and New York City Department of Health and Mental Hygiene Institutional Review Boards (IRB). The New York University School of Medicine IRB approval process encompassed detailed review by the IRB prisoners’ advocate.

Consent for publication: Not applicable.

Availability of data and material: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests

Funding: This work was funded by a Gilead Sciences Investigator Sponsored Research grant. Dr. Akiyama is also supported by a Pathway to Independence Award from the National Institute on Drug Abuse (K99DA043011).

Authors' contributions: MJA and DC drafted the manuscript. MJA, RM, and EC devised the study concept and design. Data acquisition was conducted by MJA, DC, JS. Data analysis was conducted by JS. All authors conducted critical revisions of the manuscript for important intellectual content.
Acknowledgements: Not applicable.

References

1. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology (Baltimore, Md). 2015;62(5):1353-1363.

2. Varan AK, Mercer DW, Stein MS, Spaulding AC. Hepatitis C seroprevalence among prison inmates since 2001: still high but declining. Public Health Rep. 2014;129(2):187-195.

3. Rich JD, Allen SA, Williams BA. Responding to hepatitis C through the criminal justice system. The New England journal of medicine. 2014;370(20):1871-1874.

4. Murray KF, Richardson LP, Morishima C, Owens JW, Gretch DR. Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: a pilot study. Pediatrics. 2003;111(1):153-157.

5. Nyamathi A, Salem BE, Marlow E, Zhang S, Yadav K. Understanding correlates of hepatitis C virus infection among homeless recently paroled men. J Forensic Nurs. 2013;9(3):161-170.

6. Hudson AL, Nyamathi A, Bhattacharya D, et al. Impact of prison status on HIV-related risk behaviors. AIDS and behavior. 2011;15(2):340-346.

7. Cuadrado A, Llerena S, Cobo C, et al. Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. Am J Gastroenterol. 2018.

8. Spaulding AC, Perez SD, Seals RM, Hallman MA, Kavasery R, Weiss PS. Diversity of release patterns for jail detainees: implications for public health interventions. Am J Public Health. 2011;101 Suppl 1:S347-352.

9. MacDonald R, Akiyama MJ, Kopolow A, et al. Feasibility of Treating Hepatitis C in a Transient Jail Population. Open Forum Infect Dis. 2017;4(3):ofx142.

10. Subramanian R, Delaney R, Roberts S, Fishman N, P. M. Incarceration’s Front Door: The Misuse of Jails in America. New York, NY: VERA Institute of Justice;2015.

11. Iroh PA, Mayo H, Nijhawan AE. The HIV Care Cascade Before, During, and After Incarceration: A
12. Nunn A, Cornwall A, Fu J, Bazerman L, Loewenthal H, Beckwith C. Linking HIV-positive jail inmates to treatment, care, and social services after release: results from a qualitative assessment of the COMPASS Program. *J Urban Health*. 2010;87(6):954-968.

13. Rapp RC, Ciomcia R, Zaller N, Draine J, Ferguson A, Cagey R. The role of jails in engaging PLWHA in care: from jail to community. *AIDS and behavior*. 2013;17 Suppl 2:S89-99.

14. Avery A, Ciomica R, Gierlach M, Machekano R. Jail-Based Case Management Improves Retention in HIV Care 12 Months Post Release. *AIDS and behavior*. 2018.

15. Gardner LI, Metsch LR, Anderson-Mahoney P, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. *AIDS*. 2005;19(4):423-431.

16. Teixeira PA, Jordan AO, Zaller N, Shah D, Venters H. Health outcomes for HIV-infected persons released from the New York City jail system with a transitional care-coordination plan. *Am J Public Health*. 2015;105(2):351-357.

17. Loeliger KB, Meyer JP, Desai MM, Ciarleglio MM, Gallagher C, Altice FL. Retention in HIV care during the 3 years following release from incarceration: A cohort study. *PLoS Med*. 2018;15(10):e1002667.

18. Jordan AO, Cohen LR, Harriman G, Teixeira PA, Cruzado-Quinones J, Venters H. Transitional care coordination in New York City jails: facilitating linkages to care for people with HIV returning home from Rikers Island. *AIDS and behavior*. 2013;17 Suppl 2:S212-219.

19. Myers JJ, Koester KA, Kang Dufour MS, Jordan AO, Cruzado-Quinone J, Riker A. Patient navigators effectively support HIV-infected individuals returning to the community from jail settings. *Int J Prison Health*. 2017;13(3-4):213-218.

20. Myers JJ, Kang Dufour MS, Koester KA, et al. The Effect of Patient Navigation on the Likelihood of Engagement in Clinical Care for HIV-Infected Individuals Leaving Jail. *Am J Public Health*. 2018;108(3):385-392.

21. New York City Department of Corrections. *DOC Statistics* https://www1.nyc.gov/site/doc/about/doc-statistics.page. Accessed March 1st, 2018.
22. New York City Department of Corrections. *New York City Department of Corrections Inmate Lookup Service*

http://a073-ils-web.nyc.gov/inmatelookup/pages/common/find.jsf. Accessed March 1st, 2018.

23. New York State Department of Corrections. *New York State Department of Corrections Inmate Lookup*

http://nysdoccslookup.doccs.ny.gov Accessed March 1st, 2018.

24. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009;42(2):377-381.

25. Beckwith CG, Kurth AE, Bazerman LB, et al. A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections. *J Public Health (Oxf).* 2016;38(1):130-137.

26. Cocoros N, Nettle E, Church D, et al. Screening for Hepatitis C as a Prevention Enhancement (SHAPE) for HIV: an integration pilot initiative in a Massachusetts County correctional facility. *Public Health Rep.* 2014;129 Suppl 1:5-11.

27. Schoenbachler BT, Smith BD, Sena AC, et al. Hepatitis C Virus Testing and Linkage to Care in North Carolina and South Carolina Jails, 2012-2014. *Public Health Rep.* 2016;131 Suppl 2:98-104.

28. New York City Human Resources Administration. HIV/AIDS Services. 2018;

https://www1.nyc.gov/site/hra/help/hiv-aids-services.page. Accessed July 1st, 2018.

29. Ammon B, Iroh P, Tiruneh Y, et al. HIV Care After Jail: Low Rates of Engagement in a Vulnerable Population. *J Urban Health.* 2018;95(4):488-498.

30. Loeliger KB, Altice FL, Desai MM, Ciarleglio MM, Gallagher C, Meyer JP. Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study. *Lancet HIV.* 2018;5(2):e96-e106.

31. Molitor F, Waltermeyer J, Mendoza M, et al. Locating and linking to medical care HIV-positive persons without a history of care: findings from the California Bridge Project. *AIDS Care.* 2006;18(5):456-459.
32. Molitor F, Kuenneth C, Waltermeyer J, et al. Linking HIV-infected persons of color and injection drug users to HIV medical and other services: the California Bridge Project. *AIDS Patient Care STDS.* 2005;19(6):406-412.

33. Merrall EL, Kariminia A, Binswanger IA, et al. Meta-analysis of drug-related deaths soon after release from prison. *Addiction (Abingdon, England).* 2010;105(9):1545-1554.

34. Adams J, Nowels C, Corsi K, Long J, Steiner JF, Binswanger IA. HIV risk after release from prison: a qualitative study of former inmates. *J Acquir Immune Defic Syndr.* 2011;57(5):429-434.

35. Bird SM, Hutchinson SJ. Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996-99. *Addiction (Abingdon, England).* 2003;98(2):185-190.

36. Kariminia A, Butler T, Corben S, et al. Extreme cause-specific mortality in a cohort of adult prisoners--1988 to 2002: a data-linkage study. *Int J Epidemiol.* 2007;36(2):310-316.

37. Binswanger IA, Stern MF, Deyo RA, et al. Release from prison--a high risk of death for former inmates. *The New England journal of medicine.* 2007;356(2):157-165.

38. Mason K, Dodd Z, Guyton M, et al. Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. *Int J Drug Policy.* 2017;47:202-208.

39. Koester KA, Morewitz M, Pearson C, et al. Patient navigation facilitates medical and social services engagement among HIV-infected individuals leaving jail and returning to the community. *AIDS Patient Care STDS.* 2014;28(2):82-90.

40. Taylor BS, Fornos L, Tarbutton J, et al. Improving HIV Care Engagement in the South from the Patient and Provider Perspective: The Role of Stigma, Social Support, and Shared Decision-Making. *AIDS Patient Care STDS.* 2018;32(9):368-378.

41. Spaulding AC, Drobeniuc A, Frew PM, et al. Jail, an unappreciated medical home: Assessing the feasibility of a strengths-based case management intervention to improve the care retention of HIV-infected persons once released from jail. *PloS one.* 2018;13(3):e0191643.

42. Lim S, Nash D, Hollod L, Harris TG, Lennon MC, Thorpe LE. Influence of Jail Incarceration and Homelessness Patterns on Engagement in HIV Care and HIV Viral Suppression among New York City
Adults Living with HIV/AIDS. *PloS one.* 2015;10(11):e0141912.

**Table**

1. Baseline participant characteristics and associations with linkage to HCV care
| Characteristics                                      | Linked to care N=26* (%) | Unlinked to care N=58* (%) | Total N = 84* (%) | P value |
|-----------------------------------------------------|--------------------------|-----------------------------|-------------------|---------|
| Age, mean (SD)                                       | 47 (11)                  | 44 (12)                     | 45 (12)           | 0.29    |
| ≥45                                                 | 14 (54)                  | 29 (50)                     | 43 (51)           | 0.74    |
| <45                                                 | 12 (46)                  | 29 (50)                     | 41 (49)           |         |
| Sex                                                 |                          |                             |                   |         |
| Female                                              | 9 (35)                   | 27 (47)                     | 36 (43)           | 0.31    |
| Male                                                | 17 (65)                  | 31 (53)                     | 48 (57)           |         |
| Race/ethnicity                                       |                          |                             |                   |         |
| Hispanic                                            | 15 (58)                  | 31 (54)                     | 46 (55)           | 0.94    |
| NH Black                                            | 5 (19)                   | 10 (18)                     | 15 (18)           |         |
| NH White                                            | 5 (19)                   | 12 (21)                     | 17 (21)           |         |
| Other                                               | 1 (4)                    | 4 (7)                       | 4 (6)             |         |
| Enrolled inpatient vs. outpatient                   | 5 (19)                   | 5 (9)                       | 10 (12)           | 0.73    |
| Health insurance prior to incarceration             | 22/26 (85)               | 45/57 (79)                  | 67/83 (81)        | 0.54    |
| Homeless                                            | 5 (19)                   | 17 (29)                     | 22 (26)           |         |
| Graduated high school                               | 14/25 (56)               | 34/55 (62)                  | 48/80 (60)        | 0.62    |
| Psychiatric diagnosis‡                              | 13 (50)                  | 40 (69)                     | 53 (63)           | 0.10    |
| Care Coordination                                   |                          |                             |                   |         |
| Personal contact info at enrollment                 | 13 (50)                  | 23 (40)                     | 36 (43)           | 0.38    |
| NOK contact info at enrollment                      | 25 (96)                  | 52 (90)                     | 77 (92)           | 0.32    |
| Known release date                                  | 14 (54)                  | 34 (59)                     | 48 (57)           | 0.68    |
| HCV appointment scheduled pre-release               | 13 (50)                  | 19 (33)                     | 32 (38)           | 0.13    |
| Existing HCV provider                               | 3/24 (13)                | 3/54 (6)                    | 6/78 (8)          | 0.29    |
| Existing primary care provider                      | 9/24 (38)                | 10/55 (18)                  | 19/79 (24)        | 0.06    |
| Prefer linkage to existing health system            | 8 (31)                   | 7 (12)                      | 15 (18)           | 0.04**  |
| Opioid agonist therapy                              |                          |                             |                   |         |
| Methadone                                           | 20 (77)                  | 30 (52)                     | 50 (60)           | 0.03**  |
| Suboxone                                            | 5 (19)                   | 19 (33)                     | 24 (29)           | 0.21    |
| Substance use                                       |                          |                             |                   |         |
| Injection drug use                                  |                          |                             |                   |         |
| 30 days prior                                       | 16 (62)                  | 35 (60)                     | 51 (61)           | 0.92    |
| Lifetime                                            | 22 (85)                  | 36 (63)                     | 58 (70)           | 0.22    |
| Heroin                                              | 13 (50)                  | 34 (59)                     | 47 (56)           | 0.46    |
| 30 days prior                                       |                          |                             |                   |         |
| Lifetime                                            | 25 (96)                  | 50 (86)                     | 75 (89)           | 0.17    |
| Prescription opiates                                | 4 (15)                   | 2 (3)                       | 6 (7)             | 0.90    |
| 30 days prior                                       |                          |                             |                   |         |
| Lifetime                                            | 14 (54)                  | 23 (40)                     | 37 (44)           | 0.22    |
| Crack/Cocaine                                       |                          |                             |                   |         |
| 30 days prior                                       | 9 (35)                   | 23 (40)                     | 32 (38)           | 0.66    |
| Lifetime                                            | 21 (81)                  | 48 (83)                     | 69 (82)           | 0.83    |
| Amphetamines                                        |                          |                             |                   |         |
| 30 days prior                                       | 0 (0)                    | 2 (3)                       | 2 (2)             | 0.33    |
| Lifetime                                            | 2 (8)                    | 8 (14)                      | 10 (12)           | 0.42    |
| Marijuana                                           |                          |                             |                   |         |
| 30 days prior                                       | 6 (23)                   | 20 (34)                     | 26 (31)           | 0.30    |
| Lifetime                                            | 15 (58)                  | 44 (76)                     | 59 (70)           | 0.09    |
| Alcohol to intoxication                             |                          |                             |                   |         |
| 30 days prior                                       | 2 (8)                    | 12 (21)                     | 14 (17)           | 0.14    |
| Lifetime                                            | 5 (16)                   | 26 (44)                     | 31 (37)           | 0.03**  |
| Social support                                      |                          |                             |                   |         |
| Feel supported socially                             | 21/25 (84)               | 37/56 (66)                  | 58/81 (72)        | 0.10    |
| Feel family or a loved one is concerned about wellbeing | 25/25 (100)             | 45/56 (64)                  | 70/81 (86)        | 0.02**  |
| Reincarcerated ≥1 time within 180 days post-release  | 8 (31)                   | 20 (36)                     | 28 (33)           | 0.86    |

‡ Includes depression, anxiety, bipolar, schizophrenia; *Unless denominator specified; **Statistically significant alpha level p<0.05. HCV = hepatitis C virus, NH = non-Hispanic, NOK = next of kin, SD = standard deviation.

Figures
Figure 1

Participant flow chart. HCV = hepatitis C virus, HIV = human immunodeficiency virus, VL = viral load, Tx = treatment
Figure 2

Hepatitis C virus (HCV) care cascade following release from New York City jails. In a cohort of 84 participants who returned to the community after incarceration, 26 (31%) linked to HCV care, 17 (20%) initiated HCV treatment, 15 (18%) completed treatment, and 7 (8%) had a documented sustained virologic response (SVR). Of the 9 participants with documented 12-week follow-up labs, this was a 78% SVR rate.
Figure 3

Trajectories of people living with HCV following release from New York City Jails. Each row in an EventFlow figure represents one participant’s sequence of events during a period of time. The height of each bar is proportional to the number of records with that sequence, and its horizontal position is determined by the median time between events. Groups of sequences with the same preceding event are sorted by the number of records in each group. The sequence groups are shown from top to bottom in descending order of number of participants per group. For interval events such as returns to jail, the length of the intervals represents the mean duration of the grouped events. For point events such as linkage to HCV care, periods between the aggregated point events represent the mean length of time from any previous point event.